MEREO BIOPHARMA GROUP PLC Cash and Cash Equivalents
MEREO BIOPHARMA GROUP PLC (MREO) had Cash and Cash Equivalents of $30.12 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2026-08-11
- 2026-06-30: Cash and Cash Equivalents, at Carrying Value $30.12M.
- 2026-03-31: Cash and Cash Equivalents, at Carrying Value $30.10M; Cash and Cash Equivalents, at Carrying Value as first filed $36.22M.
- 2025-12-31: Cash and Cash Equivalents, at Carrying Value $40.99M.
- 2025-09-30: Cash and Cash Equivalents, at Carrying Value $48.70M.
| Period end | Cash and Cash Equivalents, at Carrying Value | Cash and Cash Equivalents, at Carrying Value as first filed |
|---|---|---|
| 2026-06-30 | $30.12M 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $30.10M 10-Q · filed 2026-08-11 | $36.22M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $40.99M 10-Q · filed 2026-08-11 | |
| 2025-09-30 | $48.70M 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $56.13M 10-Q · filed 2025-08-12 | |
| 2025-03-31 | $62.48M 10-Q · filed 2025-05-13 | |
| 2024-12-31 | $69.80M 10-K · filed 2026-03-19 | |
| 2024-09-30 | $80.52M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $87.43M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $48.66M 10-Q · filed 2024-05-15 | |
| 2023-12-31 | $57.42M 10-K · filed 2025-03-26 | |
| 2022-12-31 | $68.18M 10-K · filed 2024-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |